Advertisement


Eileen Danaher Hacker, PhD, APN, AOCN: After Stem Cell Transplant: Enhancing Recovery With Strength Training

2016 Palliative Care in Oncology Symposium

Advertisement

Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois at Chicago, discusses study findings that show improvement in physical activity, fatigue, muscle strength, and functional ability (Abstract 190).



Related Videos

Global Cancer Care
Issues in Oncology
Palliative Care

Emily Haozous, PhD, RN, on Cultural Differences in End-of-Life Care

Emily Haozous, PhD, RN, of the University of New Mexico, discusses health disparities and cultural differences in palliative and end-of-life care, with case study examples drawn from American Indian communities.

Palliative Care
Issues in Oncology

Charles D. Blanke, MD, on Oregon’s Death With Dignity Act

Charles D. Blanke, MD, of the Oregon Health & Science University and Southwest Oncology Group, discusses the nearly 20 years’ experience with Oregon’s Death With Dignity (DWD) Act, a voter initiative that led to the first such law enacted in the United States (Abstract 44).

Palliative Care
Supportive Care
Issues in Oncology

Randy L. Wei, MD, PhD, on Radiation Oncologists and Palliative Care

Randy L. Wei, MD, PhD, of the University of California, Irvine, discusses findings from a survey that focused on ASTRO members who assessed their ability to deliver palliative and supportive care, and their access to continuing medical education on the topic (Abstract 105).

Palliative Care
Symptom Management

Tracy A. Balboni, MD, MPH, on Managing Spinal Metastases With Radiation Therapy

Tracy A. Balboni, MD, MPH, of the Dana-Farber Cancer Institute, talks about how to preserve quality of life in the presence of complex spinal lesions, including novel ways to assess spinal instability and treat metastases.

Palliative Care
Issues in Oncology

Jennifer S. Temel, MD, on The Changing Conversation Around Prognostication

Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses increasing prognostic uncertainty in light of targeted treatments and immunotherapies, and the difficulty predicting who will benefit.

Advertisement

Advertisement




Advertisement